The study will assess the efficacy and safety of oral MT-1303 compared to placebo at 12 weeks as the induction treatment in subjects with active mild to moderate ulcerative colitis (UC), as well as maintenance treatment with open-label MT-1303 for up to 36 weeks.
Biogen has announced an agreement to exclusively license MT-1303, a late stage experimental medicine with potential in multiple autoimmune indications,...
MT Pharma America announced the FDA has granted approval of Radicava (edaravone), as an intravenous infusion treatment for amyotrophic lateral...
Zogenix, Inc. a global pharmaceutical company developing rare disease therapies, announced that it has entered into a definitive agreement to acquire Modis...